Cargando…
Challenges for Relative Effectiveness Assessment and Early Access of Cancer Immunotherapies in Europe
Clinical endpoints relevant for relative effectiveness assessment (REA) reflect how patients feel, function, or survive. Outcome data requested by health technology assessment (HTA) bodies in Europe to support reimbursement of an anticancer drug are based on final endpoints coming from completed com...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107821/ https://www.ncbi.nlm.nih.gov/pubmed/27896268 http://dx.doi.org/10.3389/fmed.2016.00056 |